Establishment of a cost-effective method to detect FLT-ITD and D835 mutations in acute myeloid leukemia patients in the Taiwanese population

Hsingjin Eugene Liu, Ching Huai Ko, Freda Lam, Lawrence Shih Hsin Wu, Kuei Fang Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: The FMS-related tyrosine kinase 3 (FLT-3) gene is a hematopoietic growth factor receptor gene, an independent negative prognostic factor, which affects the proliferation and differentiation of stem cells or hematopoietic progenitor cells. Patients with FLT-3 gene mutations have a worse prognosis and responsiveness to chemotherapy than those without these mutations. Our study aims to establish a conventional detection method for FLT3-ITD and D835 mutations in patients with acute myeloid leukemia (AML). Materials and methods: In this study, we recruited 100 patients with AML. Primers were designed to distinguish between wild-type FLT-3, FLT3-ITD, and D835 variants. Methods using a polymerase chain reaction (PCR)-Agilent 2100 Bioanalyzer, PCR-ABI PRISM 3100 Genetic Analyzer, and PCR-agarose gel electrophoresis were compared. Results: A high-accuracy, easily operated, low-cost technique to detect the FLT-3 variation with 99.9% specificity was established in this study. The PCR platform, the Agilent 2100 Bioanalyzer (plus DNA 1000 LabChip kit) chip analysis platform, and the ABI PRISM 3100 Genetic Analyzer (plus GeneScan-500 size standard) short tandem repeat (STR) fluorescence analysis platform were used in different experimental comparisons. The ABI PRISM 3100 Genetic Analyzer (plus GeneScan-500 size standard) STR fluorescence analysis platform was the most suitable method to detect FLT3 variants. This method has a high degree of sensitivity, accuracy, and a specificity of 99.9%. Conclusion: AML with the homozygous mutated FLT-3 may have a worse cure rate than AML with heterozygous mutation. This mutation is not related to drug resistance, but is a factor in a high risk of relapse; it is also related to unfavorable overall survival. Our designed detection methods should provide key information to develop personalized medicine for AML patients.

Original languageEnglish
Pages (from-to)18-24
Number of pages7
JournalTzu Chi Medical Journal
Volume27
Issue number1
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Costs and Cost Analysis
Mutation
Population
Polymerase Chain Reaction
Microsatellite Repeats
Colony-Stimulating Factor Receptors
Fluorescence
Genes
Precision Medicine
Agar Gel Electrophoresis
Hematopoietic Stem Cells
Drug Resistance
Stem Cells
Recurrence
Drug Therapy
Survival
DNA

Keywords

  • Acute myeloid leukemia
  • FLT3-D835
  • FLT3-ITD

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Establishment of a cost-effective method to detect FLT-ITD and D835 mutations in acute myeloid leukemia patients in the Taiwanese population. / Liu, Hsingjin Eugene; Ko, Ching Huai; Lam, Freda; Wu, Lawrence Shih Hsin; Lee, Kuei Fang.

In: Tzu Chi Medical Journal, Vol. 27, No. 1, 01.03.2015, p. 18-24.

Research output: Contribution to journalArticle

@article{890fffb54a7c47868b37b41ec052d680,
title = "Establishment of a cost-effective method to detect FLT-ITD and D835 mutations in acute myeloid leukemia patients in the Taiwanese population",
abstract = "Objective: The FMS-related tyrosine kinase 3 (FLT-3) gene is a hematopoietic growth factor receptor gene, an independent negative prognostic factor, which affects the proliferation and differentiation of stem cells or hematopoietic progenitor cells. Patients with FLT-3 gene mutations have a worse prognosis and responsiveness to chemotherapy than those without these mutations. Our study aims to establish a conventional detection method for FLT3-ITD and D835 mutations in patients with acute myeloid leukemia (AML). Materials and methods: In this study, we recruited 100 patients with AML. Primers were designed to distinguish between wild-type FLT-3, FLT3-ITD, and D835 variants. Methods using a polymerase chain reaction (PCR)-Agilent 2100 Bioanalyzer, PCR-ABI PRISM 3100 Genetic Analyzer, and PCR-agarose gel electrophoresis were compared. Results: A high-accuracy, easily operated, low-cost technique to detect the FLT-3 variation with 99.9{\%} specificity was established in this study. The PCR platform, the Agilent 2100 Bioanalyzer (plus DNA 1000 LabChip kit) chip analysis platform, and the ABI PRISM 3100 Genetic Analyzer (plus GeneScan-500 size standard) short tandem repeat (STR) fluorescence analysis platform were used in different experimental comparisons. The ABI PRISM 3100 Genetic Analyzer (plus GeneScan-500 size standard) STR fluorescence analysis platform was the most suitable method to detect FLT3 variants. This method has a high degree of sensitivity, accuracy, and a specificity of 99.9{\%}. Conclusion: AML with the homozygous mutated FLT-3 may have a worse cure rate than AML with heterozygous mutation. This mutation is not related to drug resistance, but is a factor in a high risk of relapse; it is also related to unfavorable overall survival. Our designed detection methods should provide key information to develop personalized medicine for AML patients.",
keywords = "Acute myeloid leukemia, FLT3-D835, FLT3-ITD",
author = "Liu, {Hsingjin Eugene} and Ko, {Ching Huai} and Freda Lam and Wu, {Lawrence Shih Hsin} and Lee, {Kuei Fang}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.tcmj.2014.12.005",
language = "English",
volume = "27",
pages = "18--24",
journal = "Tzu Chi Medical Journal",
issn = "1016-3190",
publisher = "財團法人中華民國佛教慈濟慈善事業基金會",
number = "1",

}

TY - JOUR

T1 - Establishment of a cost-effective method to detect FLT-ITD and D835 mutations in acute myeloid leukemia patients in the Taiwanese population

AU - Liu, Hsingjin Eugene

AU - Ko, Ching Huai

AU - Lam, Freda

AU - Wu, Lawrence Shih Hsin

AU - Lee, Kuei Fang

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Objective: The FMS-related tyrosine kinase 3 (FLT-3) gene is a hematopoietic growth factor receptor gene, an independent negative prognostic factor, which affects the proliferation and differentiation of stem cells or hematopoietic progenitor cells. Patients with FLT-3 gene mutations have a worse prognosis and responsiveness to chemotherapy than those without these mutations. Our study aims to establish a conventional detection method for FLT3-ITD and D835 mutations in patients with acute myeloid leukemia (AML). Materials and methods: In this study, we recruited 100 patients with AML. Primers were designed to distinguish between wild-type FLT-3, FLT3-ITD, and D835 variants. Methods using a polymerase chain reaction (PCR)-Agilent 2100 Bioanalyzer, PCR-ABI PRISM 3100 Genetic Analyzer, and PCR-agarose gel electrophoresis were compared. Results: A high-accuracy, easily operated, low-cost technique to detect the FLT-3 variation with 99.9% specificity was established in this study. The PCR platform, the Agilent 2100 Bioanalyzer (plus DNA 1000 LabChip kit) chip analysis platform, and the ABI PRISM 3100 Genetic Analyzer (plus GeneScan-500 size standard) short tandem repeat (STR) fluorescence analysis platform were used in different experimental comparisons. The ABI PRISM 3100 Genetic Analyzer (plus GeneScan-500 size standard) STR fluorescence analysis platform was the most suitable method to detect FLT3 variants. This method has a high degree of sensitivity, accuracy, and a specificity of 99.9%. Conclusion: AML with the homozygous mutated FLT-3 may have a worse cure rate than AML with heterozygous mutation. This mutation is not related to drug resistance, but is a factor in a high risk of relapse; it is also related to unfavorable overall survival. Our designed detection methods should provide key information to develop personalized medicine for AML patients.

AB - Objective: The FMS-related tyrosine kinase 3 (FLT-3) gene is a hematopoietic growth factor receptor gene, an independent negative prognostic factor, which affects the proliferation and differentiation of stem cells or hematopoietic progenitor cells. Patients with FLT-3 gene mutations have a worse prognosis and responsiveness to chemotherapy than those without these mutations. Our study aims to establish a conventional detection method for FLT3-ITD and D835 mutations in patients with acute myeloid leukemia (AML). Materials and methods: In this study, we recruited 100 patients with AML. Primers were designed to distinguish between wild-type FLT-3, FLT3-ITD, and D835 variants. Methods using a polymerase chain reaction (PCR)-Agilent 2100 Bioanalyzer, PCR-ABI PRISM 3100 Genetic Analyzer, and PCR-agarose gel electrophoresis were compared. Results: A high-accuracy, easily operated, low-cost technique to detect the FLT-3 variation with 99.9% specificity was established in this study. The PCR platform, the Agilent 2100 Bioanalyzer (plus DNA 1000 LabChip kit) chip analysis platform, and the ABI PRISM 3100 Genetic Analyzer (plus GeneScan-500 size standard) short tandem repeat (STR) fluorescence analysis platform were used in different experimental comparisons. The ABI PRISM 3100 Genetic Analyzer (plus GeneScan-500 size standard) STR fluorescence analysis platform was the most suitable method to detect FLT3 variants. This method has a high degree of sensitivity, accuracy, and a specificity of 99.9%. Conclusion: AML with the homozygous mutated FLT-3 may have a worse cure rate than AML with heterozygous mutation. This mutation is not related to drug resistance, but is a factor in a high risk of relapse; it is also related to unfavorable overall survival. Our designed detection methods should provide key information to develop personalized medicine for AML patients.

KW - Acute myeloid leukemia

KW - FLT3-D835

KW - FLT3-ITD

UR - http://www.scopus.com/inward/record.url?scp=84925343043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925343043&partnerID=8YFLogxK

U2 - 10.1016/j.tcmj.2014.12.005

DO - 10.1016/j.tcmj.2014.12.005

M3 - Article

AN - SCOPUS:84925343043

VL - 27

SP - 18

EP - 24

JO - Tzu Chi Medical Journal

JF - Tzu Chi Medical Journal

SN - 1016-3190

IS - 1

ER -